Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2024Journal of Clinical Oncology

Phase 1 study of AM003, a novel individualized immunotherapy, in a basket of advanced solid tumors.

View Full Paper
Ask AI
Bookmark
Share

Authors

ILIrit Carmi LevyLALeanne AmitziUniversity of British ColumbiaELErez Lavi

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Levy et al. (2024) studied this question.

synapsesocial.com/papers/68e66eefb6db6435875f976ahttps://doi.org/10.1200/jco.2024.42.16_suppl.tps2692
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Durable complete response and overall survival in patients with heavily pretreated, poor-prognosis non-Hodgkin lymphoma to immunoactivating AVM0703 with few and mild drug-related adverse effects.2024 · 1 citations
  2. 2A phase Ia, dose-escalation study of IMB071703 injection in patients (pts) with recurrent or metastatic, advanced solid tumors.2024 · 1 citations
  3. 3A phase I/II, open-label, multicenter study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of HB0036 in patients with advanced solid tumors.2024 · 4 citations
  4. 4Abstract CT097: IMM27M, a humanized Fc-engineered anti CTLA-4 antibody, in patients with advanced solid tumors: A phase I dose-escalation study2024
  5. 5First-in-human study of DM002, an anti-MUC1/HER3 bispecific antibody-drug conjugate, in patients with advanced solid tumors.2026